Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
National Institute for Health and Care Excellence (NICE)
Record ID 32018012027
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta950
Year Published:
2024
URL for published report:
https://www.nice.org.uk/guidance/ta950
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Melanoma
- Nivolumab
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Adolescent
- Adult
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.